Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says

Executive Summary

FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.

You may also be interested in...



Deal Watch: Taking Care Of Business Before J.P. Morgan

Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.

Actavis’ Big Bet On A Diversified Hybrid Model

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports

A two-year patent infringement case reached a conclusion with the Delhi High Court favoring Natco in a dispute over generic versions of Teva’s top-selling MS drug. If the court had sided with Teva, launch plans for the United States may have been delayed for Natco’s partner Mylan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel